• $66.4M
    Market Cap
  • 218.09%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 84
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

ALPHEA Secures $5M Strategic Funding

ALPHEA, a platform building infrastructure for AI agents, has secured $5 million in strategic funding from investors including MH Ventures, IBC Ventures, Titan Ventures, and Becker Ventures. The funding will accelerate product development and expand ALPHEA's global node ecosystem, enabling AI agents to run, collaborate, store data, and settle value efficiently in a distributed cloud environment designed specifically for autonomous AI operations.

07/24/2026, 10:52 AM • GlobeNewswire

ALPHEA Secures $5M Strategic Funding

ALPHEA, an AI infrastructure platform, has raised $5 million in strategic funding from investors including MH Ventures, IBC Ventures, Titan Ventures, and Becker Ventures. The funding will accelerate development of ALPHEA's AI-native distributed cloud designed specifically for autonomous agents, with plans to expand its global node ecosystem and improve developer tools.

07/24/2026, 3:02 AM • GlobeNewswire

Peers

  • IBIO
    IBIO
    $1.43+2.14%
    Market Cap$69.5M
    1-Year Change+112.44%
  • SCYX
    SCYNEXIS
    $4.80-0.77%
    Market Cap$48.1M
    1-Year Change-11.17%
  • NTRB
    NUTRIBAND
    $2.83-0.53%
    Market Cap$34.6M
    1-Year Change-61.43%
  • MIRA
    MIRA PHAR
    $0.83+4.24%
    Market Cap$33.3M
    1-Year Change-48.57%
  • PIII
    P3 HEALTH PTR-A
    $10.49+6.71%
    Market Cap$32.7M
    1-Year Change+33.74%
  • RVP
    Retractable Tech
    $0.68+2.97%
    Market Cap$19.8M
    1-Year Change-11.12%
  • COSM
    COSMOS HEALTH
    $0.22+1.95%
    Market Cap$13.4M
    1-Year Change-75.03%
  • INTS
    INTENSITY THERP
    $4.35+4.89%
    Market Cap$11.2M
    1-Year Change-30.54%
  • APUS
    APIMEDS PHARMA
    $5.16+0.19%
    Market Cap$7.8M
    1-Year Change-70.40%

Statistics

More
Day Range
$1.28
$1.41
$1.28
1-Year Range
$0.39
$1.46
$1.28
Latest Close$1.28
Change
-$0.07 (-5.86%)
Volume197,348
Market Cap$66.4M
Shares Outstanding51.9M
P/E (TTM)-4.78
Diluted EPS (TTM)-$0.27
Enterprise Value$62.6M

Information as of 07/31/2026

Company Profile

TALPHERA INC
https://talphera.com
$66.4M
Market Cap
-$14.3M
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
1850 Gateway Drive, San Mateo, CA, United States, 94404
650 216 3500

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Key Executives

  • Vincent J. Angotti
  • Raffi Mark Asadorian
  • Shakil Aslam
  • Anil N. Dasu

Current Ownership Distribution

  • Institutions81.1M (73.04%)
  • Insiders29.2M (26.25%)
  • Mutual Funds782,523 (0.70%)
  • Other0 (0.00%)